Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05739110

HCC Staging Modified by Tumor Micronecrosis

Conditions: Hepatocellular Carcinoma

Sex: All
Ages: 18 Years – 80 Years
Enrollment: 1100
Sponsor: Zhejiang University

Location: China

Summary

Tumor micronecrosis is a pathological feature that reflects malignant biological behavior in hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic significance of tumor micronecrosis based on the current BCLC and TNM staging systems, and futher improve the performance of the staging models by establishing modified new staging models including tumor micronecrosis.

Eligibility Criteria

Inclusion Criteria:primary and histologically confirmed HCCspatients who underwent curative liver resectionExclusion Criteria:simultaneous presence of other tumorspatients who had received preoperative antitumor therapiesno available surgical specimens for evaluating micronecrosis statusgross tumor necrosis and Nscore = 3

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05739110). StuddyBuddy aggregates publicly available trial information.